Key Events This Week
Jan 21: Death Cross formation signalling bearish trend
Jan 22: Technical downgrade with Mojo Grade shifting to Sell
Jan 23: Week closes at Rs.8,305.85 (+0.65%) outperforming Sensex
Monday, 19 January 2026: Modest Gain Amid Sensex Decline
Astrazeneca Pharma India Ltd opened the week on a positive note, closing at Rs.8,287.35, up 0.43% from the previous Friday’s close of Rs.8,251.95. This gain contrasted with the Sensex’s 0.49% decline to 36,650.97, signalling early relative strength in the stock despite broader market weakness. The volume was moderate at 192 lakhs, indicating steady investor interest.
Tuesday, 20 January 2026: Profit Booking Amid Market Sell-Off
The stock reversed course on Tuesday, slipping 0.45% to Rs.8,249.70 as the Sensex plunged 1.82% to 35,984.65 amid broader market concerns. The volume increased to 350 lakhs, suggesting heightened selling pressure. This decline aligned with the market’s negative sentiment, reflecting cautious investor behaviour ahead of key technical developments.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Wednesday, 21 January 2026: Death Cross Formation Signals Bearish Trend
On Wednesday, Astrazeneca Pharma India Ltd closed marginally higher at Rs.8,252.25 (+0.03%), while the Sensex declined 0.47% to 35,815.26. Despite the near-flat price movement, the stock’s chart revealed a significant technical development: the formation of a Death Cross, where the 50-day moving average crossed below the 200-day moving average. This event is widely regarded as a bearish signal, indicating weakening medium to long-term momentum and raising concerns about potential sustained price weakness.
The Death Cross coincided with a downgrade in the stock’s Mojo Grade to Sell as of 2 January 2026, reflecting a reassessment of risk amid elevated valuation metrics. Astrazeneca Pharma India Ltd’s price-to-earnings ratio stands at 88.93, well above the industry average of 32.12, suggesting that the stock is priced for strong growth expectations that may now be under pressure.
Thursday, 22 January 2026: Technical Downgrade Amid Mixed Price Action
The stock rebounded on Thursday, gaining 1.15% to close at Rs.8,347.05, its weekly high, while the Sensex rose 0.76% to 36,088.66. This intraday strength was accompanied by a technical downgrade that confirmed bearish momentum across multiple indicators. The weekly Moving Average Convergence Divergence (MACD) turned decisively bearish, and the Know Sure Thing (KST) indicator also signalled negative momentum on the weekly chart.
Despite the short-term gain, the overall technical picture remained cautious. Daily moving averages turned bearish, and Bollinger Bands showed a mildly bearish stance on the weekly timeframe. The stock’s Mojo Score of 43.0 and Sell rating underscore the market’s cautious stance amid these mixed signals.
Friday, 23 January 2026: Week Closes Slightly Lower Amid Market Weakness
On the final trading day of the week, Astrazeneca Pharma India Ltd slipped 0.49% to Rs.8,305.85, while the Sensex fell 1.33% to 35,609.90. The stock’s weekly gain of 0.65% thus outperformed the Sensex’s 3.31% decline, highlighting relative resilience despite the bearish technical backdrop. Volume increased to 260 lakhs, reflecting active trading as investors digested the week’s developments.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-01-19 | Rs.8,287.35 | +0.43% | 36,650.97 | -0.49% |
| 2026-01-20 | Rs.8,249.70 | -0.45% | 35,984.65 | -1.82% |
| 2026-01-21 | Rs.8,252.25 | +0.03% | 35,815.26 | -0.47% |
| 2026-01-22 | Rs.8,347.05 | +1.15% | 36,088.66 | +0.76% |
| 2026-01-23 | Rs.8,305.85 | -0.49% | 35,609.90 | -1.33% |
Key Takeaways
Positive Signals: Astrazeneca Pharma India Ltd outperformed the Sensex by 3.36% over the week, closing with a modest gain of 0.65% despite a broadly weak market. The stock’s weekly high of Rs.8,347.05 on 22 January demonstrated short-term buying interest and potential support near current levels.
Cautionary Signals: The formation of a Death Cross on 21 January and the downgrade to a Mojo Grade of Sell highlight deteriorating medium-term momentum. Multiple technical indicators including MACD and KST confirm bearish trends, while the elevated P/E ratio of 88.93 suggests valuation risks. The stock’s recent underperformance over the past month and year-to-date period further emphasises the cautious outlook.
Why settle for Astrazeneca Pharma India Ltd? SwitchER evaluates this small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Conclusion
Astrazeneca Pharma India Ltd’s week was characterised by a delicate balance between relative price resilience and emerging technical caution. While the stock managed to outperform the Sensex with a 0.65% gain, the formation of a Death Cross and a downgrade to a Sell rating reflect weakening momentum and elevated risk. Investors should remain vigilant of these bearish signals amid the stock’s high valuation and recent underperformance over shorter timeframes.
Monitoring key technical indicators and price action in the coming weeks will be essential to assess whether Astrazeneca Pharma India Ltd can stabilise and reverse its bearish trend or if further downside pressure will prevail.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
